ADC Therapeutics SA ADCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
-
These beaten-down stocks could bounce back in January, if history is any guide
-
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
-
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
-
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
Trading Information
- Previous Close Price
- $1.49
- Day Range
- $1.40–1.51
- 52-Week Range
- $0.78–4.98
- Bid/Ask
- $1.33 / $1.56
- Shares Outstanding
- 127.67M
- Market Cap
- $178.73M
- Volume/Avg
- 799,525 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 193
- Website
- https://www.adctherapeutics.com
Valuation
|
Metric
|
ADCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.62 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADCT
|
|---|---|
Quick Ratio | 2.86 |
Current Ratio | 3.03 |
Interest Coverage | −1.03 |
Quick Ratio
ADCT
Profitability
|
Metric
|
ADCT
|
|---|---|
Return on Assets (Normalized) | −24.93% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ADCT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|?Z>l?cq | LOCK|$&C!G | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|vdGl!yP | LOCK|&NSQ$ | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|k#>S>#F | LOCK|l@ | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|gBVgd%T? | LOCK|BVh | $33B | |||
| Viatris Inc
VTRS
| LOCK|t??@n<F | LOCK|<H! | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|jm? | LOCK|<$ | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|>h&@FK% | LOCK|@zP | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|W?Tj^T | LOCK|<? | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|K^$^># | LOCK|!RR& | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|&!^!xc@ | LOCK|^!b | $2B |
United States